tradingkey.logo
tradingkey.logo
Search

Pacific Biosciences of California Inc

PACB
Add to Watchlist
1.120USD
-0.090-7.44%
Close 05/15, 16:00ETQuotes delayed by 15 min
347.87MMarket Cap
LossP/E TTM

Pacific Biosciences of California Inc

1.120
-0.090-7.44%

More Details of Pacific Biosciences of California Inc Company

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Pacific Biosciences of California Inc Info

Ticker SymbolPACB
Company namePacific Biosciences of California Inc
IPO dateOct 27, 2010
CEOHenry (Christian O)
Number of employees575
Security typeOrdinary Share
Fiscal year-endOct 27
Address1305 O'brien Drive
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone16505218000
Websitehttps://www.pacb.com/
Ticker SymbolPACB
IPO dateOct 27, 2010
CEOHenry (Christian O)

Company Executives of Pacific Biosciences of California Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.25M
+9.33%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
132.82K
+17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
132.82K
+17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
22.82K
--
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--
Ms. Kathy P. Ordonez
Ms. Kathy P. Ordonez
Independent Director
Independent Director
--
--
Mr. Mark Van Oene
Mr. Mark Van Oene
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.25M
+9.33%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
132.82K
+17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
132.82K
+17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
22.82K
--
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumable revenue
81.94M
51.21%
Instrument revenue
53.82M
33.64%
Service And Other
24.25M
15.15%
By RegionUSD
Name
Revenue
Proportion
North America
72.80M
45.50%
Europe (including the Middle East and Africa)
44.05M
27.53%
Asia Pacific
43.16M
26.97%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumable revenue
81.94M
51.21%
Instrument revenue
53.82M
33.64%
Service And Other
24.25M
15.15%

Shareholding Stats

Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
Other
68.81%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
Other
68.81%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.22%
Investment Advisor/Hedge Fund
10.46%
Hedge Fund
8.97%
Holding Company
6.58%
Research Firm
2.49%
Individual Investor
1.15%
Corporation
1.13%
Venture Capital
0.20%
Bank and Trust
0.17%
Other
34.63%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
540
192.85M
62.12%
-19.48M
2025Q4
549
169.06M
56.00%
-65.22M
2025Q3
566
166.98M
55.32%
-97.69M
2025Q2
600
214.62M
71.52%
-110.62M
2025Q1
629
227.30M
75.82%
-104.21M
2024Q4
625
258.31M
94.32%
-61.55M
2024Q3
618
231.32M
84.94%
-85.30M
2024Q2
629
240.26M
88.29%
-64.03M
2024Q1
637
265.38M
97.57%
-38.04M
2023Q4
643
276.71M
103.53%
-9.49M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
37.26M
12.34%
+6.34M
+20.50%
Dec 31, 2025
SoftBank Group Corp
20.45M
6.77%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
20.30M
6.72%
+431.05K
+2.17%
Dec 31, 2025
Geode Capital Management, L.L.C.
7.08M
2.34%
+172.09K
+2.49%
Dec 31, 2025
Amova Asset Management Co., Ltd.
7.81M
2.59%
-868.98K
-10.01%
Dec 31, 2025
State Street Investment Management (US)
5.91M
1.96%
+2.58K
+0.04%
Dec 31, 2025
D. E. Shaw & Co., L.P.
4.44M
1.47%
+4.44M
--
Dec 31, 2025
Millennium Management LLC
4.34M
1.44%
-572.23K
-11.64%
Dec 31, 2025
Point72 (DIFC) Ltd
4.27M
1.41%
+1.81M
+73.65%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
2.3%
iShares Genomics Immunology and Healthcare ETF
1.31%
Invesco NASDAQ Future Gen 200 ETF
0.96%
Global X Genomics & Biotechnology ETF
0.69%
ARK Innovation ETF
0.58%
AXS Green Alpha ETF
0.58%
WisdomTree BioRevolution Fund
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
View more
ARK Genomic Revolution ETF
Proportion2.3%
iShares Genomics Immunology and Healthcare ETF
Proportion1.31%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.96%
Global X Genomics & Biotechnology ETF
Proportion0.69%
ARK Innovation ETF
Proportion0.58%
AXS Green Alpha ETF
Proportion0.58%
WisdomTree BioRevolution Fund
Proportion0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI